Gene Therapy for Acute Liver Failure

被引:5
|
作者
Zhu, Chuan-Long [1 ]
Li, Yu-Wen [2 ]
Gao, Ren-Tao [1 ]
机构
[1] Anhui Med Univ, Affiliated Prov Hosp, Dept Infect Dis, Hefei 230001, Peoples R China
[2] Anhui Med Univ, Affiliated Prov Hosp, Dept Pediat, Hefei 230001, Peoples R China
基金
中国国家自然科学基金;
关键词
acute liver failure; gene therapy; viral vector; hydrodynamic gene delivery; small interfering RNA; liver transplantation; FULMINANT HEPATIC-FAILURE; NECROSIS-FACTOR-ALPHA; HYDRODYNAMICS-BASED TRANSFECTION; LIPID-MEDIATED TRANSFECTION; HEPATOCYTE GROWTH-FACTOR; A20 PROTECTS MICE; NONVIRAL VECTORS; ANIMAL-MODELS; FAS LIGAND; KAPPA-B;
D O I
10.2174/156652310791111029
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Acute liver failure (ALF) is a life-threatening medical emergency and occurs when the liver rapidly loses its function within a short period. ALF can develop secondary to a variety of causes. Currently, the orthotopic liver transplantation is the "Gold Standard" therapy for the disease. However, due to the limited availability of donor organs and rapid progression of the disease, the mortality of ALF remains high. Therefore, it is imperative to develop novel therapeutic reagents for ALF. Gene therapy by delivering a target gene to the patients appears to be a promising approach for the treatment of ALF. Here, we review the recent advance of gene therapy for ALF, focusing on the three technical elements, animal models, vehicles for gene delivery and technique for gene delivery, which are important for the success of gene therapy as well as the potential targets used for the treatment of ALF.
引用
收藏
页码:156 / 166
页数:11
相关论文
共 50 条
  • [1] Gene therapy for acute liver failure by hepatocyte growth factor
    Nomi, T
    Shiota, G
    Oyama, K
    Kawasaki, H
    GASTROENTEROLOGY, 1999, 116 (04) : A645 - A645
  • [2] Acute liver failure failure post gene therapy in spinal muscular atrophy
    Satyam, P.
    Krishna, G.
    Babu, R. Ramesh
    Maganthi, M.
    Mathew, A.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [3] AMPLIFICATION OF TRANSPLANTED HEPATOCYTE MASS IN LIVER FOR GENE-THERAPY AND ACUTE LIVER-FAILURE
    GUPTA, S
    LEE, CD
    YERNENI, PR
    ARAGONA, E
    BURK, RD
    RAJVANSHI, P
    GASTROENTEROLOGY, 1994, 106 (04) : A902 - A902
  • [4] Course and therapy of acute liver failure
    Leifeld, L.
    Merk, Ph.
    Schmitz, V.
    Nattermann, J.
    Kalff, J. C.
    Hirner, A.
    Sauerbruch, T.
    Spengler, U.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2008, 13 (02) : 87 - 91
  • [5] Lactulose therapy in acute liver failure
    Alba, L
    Hay, JE
    Angulo, P
    Lee, WM
    JOURNAL OF HEPATOLOGY, 2002, 36 : 33 - 33
  • [6] Specific therapy in acute liver failure
    Canbay, A
    Gerken, G
    MEDIZINISCHE KLINIK, 2006, 101 : 111 - 114
  • [7] Acute liver failure and development of liver support therapy
    Neuhaus, P
    HEPATOLOGY 2000: SYMPOSIUM IN HONOR OF GUSTAV PAUMGARTNER, 2001, 117 : 305 - 306
  • [8] Prometheus® liver therapy in children with acute liver failure
    J Vande Walle
    S Claus
    E Snauwaert
    J De Rudder
    A Raes
    M Dick
    A Prytula
    W Van Biesen
    S Eloot
    Critical Care, 19 (Suppl 1):
  • [9] Gene therapy for acute renal failure
    Torras, Juan
    Cruzado, Josep M.
    Herrero-Fresneda, Immaculada
    Grinyo, Josep M.
    GENE THERAPY FOR RENAL DISEASES AND TRANSPLANTATION, 2008, 159 : 96 - 108
  • [10] Acute liver failure in a patient with methotrexate therapy
    Polo, JCP
    Andrés, AG
    Vela, P
    Niveiro, M
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2002, 94 (07) : 440 - 441